Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
100%(1 trials)

Phase Distribution

Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Recruiting2
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

recruiting250%
unknown125%
completed125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingnot_applicable

Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt

NCT07359547
completed

PRESERFLO® MicroShunt Extension Study

NCT04333433
unknown

Visual Field Progression and RNFL Change After PreserFlo MicroShunt Implantation

NCT06174324
recruiting

NorMIGS - a Study of Micro-invasive Glaucoma Surgery

NCT05340647

Clinical Trials (4)

Showing 4 of 4 trials
NCT07359547Not Applicable

Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt

Recruiting
NCT04333433

PRESERFLO® MicroShunt Extension Study

Completed
NCT06174324

Visual Field Progression and RNFL Change After PreserFlo MicroShunt Implantation

Unknown
NCT05340647

NorMIGS - a Study of Micro-invasive Glaucoma Surgery

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4